BDR Pharma launches affordable drug to treat ovarian, prostate cancers

Mumbai-based BDR Pharmaceutical has launched BDPARIB (RUCAPARIB) to treat advanced ovarian and prostate cancers. BDPARIB is the first affordable generic in India available in the form of a tablet, with the cost of therapy less expensive than any existing drugs in the market. The product is priced at Rs 54,000 (bottle of 60) for 300 mg dose & Rs 45,000 (bottle of 60) for 200 mg dose. RUCAPARIB is an oral, smallmolecule inhibitor of poly (ADP-ribose) polymerase (PARP) 1, 2, and 3 used as a monotherapy and in conjunction with other anti-cancer agents in several tumour forms, including ovarian and prostate cancers. It has played a significant role in treating ovarian cancer patients with BRCA mutation (germline or somatic) associated with epithelial ovarian, fallopian tube, or primary peritoneal cancer who have been treated with two or more chemotherapies.